<DOC>
	<DOCNO>NCT00124566</DOCNO>
	<brief_summary>The purpose study assess efficacy safety irofulven-based regimen compare mitoxantrone plus prednisone patient hormone-refractory prostate cancer ( HRPC ) whose disease progress follow Taxotere base regimen .</brief_summary>
	<brief_title>Study Irofulven Patients With Hormone-refractory Prostate Cancer</brief_title>
	<detailed_description>For every five patient randomize , two receive treatment number 1 ( irofulven + prednisone ) , two patient receive treatment number 2 ( irofulven + capecitabine ( Xeloda® ) + prednisone ) , one patient receive treatment number 3 ( mitoxantrone + prednisone ) . This blind study , patient doctor know treatment assign .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>To include study , patient must meet following criterion : 1 . Cancer prostate confirm biopsy sample . 2 . 18 year age old . 3 . Disease must spread beyond prostate prove chest x ray , abdominal pelvic compute tomography ( CT ) scan , bone scan clinical examination . 4 . At least one prior hormonal treatment document disease progression hormone therapy . 5 . One previous line chemotherapy include Taxotere® ( monotherapy combination ) . This could addition estramustine single agent therapy . 6 . Disease progression prior Taxoterebased therapy within 3 month discontinue . 7 . Recovered toxic effect prior chemotherapy , radiotherapy surgery . 8 . Recovered toxic effect associate investigational drug , applicable . 9 . Signed informed consent obtain prior initiation studyspecific procedure treatment . Patients participate study follow apply : 1 . Unable use prednisone . 2 . Prior treatment irofulven , capecitabine ( Xeloda ) , continuous/protracted infusion 5FU ( 5fluorouracil ) ( infusion duration great equal 24 hour ) , fluoropyrimidines mitoxantrone . 3 . Ongoing treatment corticosteroid prednisoneequivalent dose &gt; 10 mg/day . 4 . More 1 prior treatment either 153Sm 89Sr , radioisotope treatment within 8 week prior enter study . 5 . Initiation treatment bisphosphonate agent ( e.g. , pamidronate , etidronate ) within 2 month enter study . Preexisting treatment bisphosphonate agent continue study . 6 . Treatment warfarin and/or phenytoin within 14 day enter study study period . Please note : There additional inclusion/exclusion criterion . The study center determine patient meet criterion . If patient qualify trial , study personnel explain reason . If patient qualify , study personnel explain trial detail answer question . Patients decide wish participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Irofulven</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
</DOC>